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Background: The primary purpose of this study was to evaluate compliance, side effects, and safety associated with
prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms (AAAs). A
secondary goal was to determine how treatment with doxycycline influences circulating levels of matrix metalloproteinase-
9 (MMP-9) in this patient population.
Methods: Thirty-six patients with AAAs (30 men and 6 women; mean age, 69  1 years) were enrolled into a 6-month
phase II study to evaluate treatment with doxycycline (100 mg orally twice a day). Aneurysm size was measured before
and after treatment, and compliance and side effects were monitored. Plasma levels of doxycycline were measured midway
through the study, and plasma MMP-9 concentrations were measured at baseline, 3 months, and 6 months.
Results: Thirty-three of the 36 patients (92%) completed 6 months of doxycycline treatment. Significant treatment-related
side effects occurred in five patients (13.9%), including three with cutaneous photosensitivity reactions (8.3%), one with
tooth discoloration (2.8%), and one with yeast infection (2.8%). A high rate of compliance with treatment was seen,
despite minor but frequent side effects, including nonspecific gastrointestinal symptoms (25%), easily managed episodes
of photosensitivity (22.2%), and reversible tooth discoloration (5.5%). The mean plasma doxycycline level after 3 months
was 4.62  0.68 ug/mL (median, 3.64 g/mL; range, 1.31 to 14.39 g/mL; n  23 patients). No significant change
was seen in AAA diameter (42.7  1.3 mm at 6 months versus 41.0  0.9 mm at baseline), and the overall rate of AAA
expansion was 0.63%  0.25% per month. The mean plasma MMP-9 level (n  19 patients) was elevated at baseline
(118.9  37.9 ng/mL; upper limit of normal, 85 ng/mL) but subsequently decreased to 83.8  32.9 ng/mL at 3
months (not signifcant versus baseline) and to 66.4  24.2 ng/mL at 6 months (P  .022 versus baseline). Only 21% of
patients had an elevated level of plasma MMP-9 after 6 months of treatment compared with 47% at baseline (P < .05).
Conclusion: Prolonged administration of doxycycline is safe and well tolerated by patients with small asymptomatic AAAs
and is associated with a gradual reduction in plasma MMP-9 levels. Further studies are needed to evaluate the long-term
effects of doxycycline on the rate and extent of aneurysm growth and the potential use of plasma MMP-9 levels as a
biomarker of aneurysm disease progression. (J Vasc Surg 2002;36:1-12.)
Abdominal aortic aneurysms (AAAs) represent a
chronic degenerative condition associated with aging, ath-
erosclerosis, smoking, and chronic obstructive pulmonary
disease and an undefined familial predisposition.1 Current
treatment for AAAs is aimed at eliminating deaths from
aneurysm rupture, either with segmental graft replacement
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or endoluminal exclusion of the diseased aorta. Elective
repair of AAAs is reserved for patients with large AAAs, with
two prospective clinical trials recently showing that long-
term survival rate is not improved with repair of AAAs less
than 5.5 cm in diameter.2,3 At the same time, ultrasound
scan screening studies reveal that AAAs occur in up to 9% of
the population of more than 65 years of age.4 Most of these
lesions are too small to warrant elective repair, yet their
natural history is one of gradual expansion.5 Although
various risk factors for aneurysm expansion and rupture
have been described,6,7 presently no form of treatment is
known to reduce the rate or extent of aneurysm expansion
in patients with small asymptomatic AAAs.
Numerous studies show that aneurysmal degeneration
is associated with chronic inflammation and destruction of
structural matrix proteins within the aortic wall.1,8 In-
creased local production of matrix metalloproteinases
(MMPs) has been implicated in this process, particularly
enzymes capable of degrading elastin and interstitial colla-
gens (ie, MMP-2/gelatinase A, MMP-9/gelatinase B,
MMP-12/macrophage elastase, MMP-1/fibroblast colla-
genase, MMP-13/collagenase-3, and MMP-14/mem-
brane type-1 MMP).9 MMP-9/gelatinase B has attracted
particular attention as a potential mediator of aneurysm
disease because it is expressed by aneurysm-infiltrating
macrophages at the site of tissue damage in both human
AAAs and in experimental aneurysm tissues10-12 and be-
cause aortic wall levels of MMP-9 expression are correlated
with aneurysm diameter.13,14 Pharmacologic suppression
of experimental AAAs also is associated with a reduction in
tissue MMP-9 expression,15,16 and aneurysmal degenera-
tion is specifically suppressed with targeted deletion of the
MMP-9 gene in murine models of AAAs.17,18 Although
these findings indicate that MMP-9 may be necessary in
aneurysmal degeneration, circulating levels of MMP-9 also
are elevated in at least 50% of patients with AAAs19,20;
moreover, a decrease in plasma MMP-9 levels after open or
endovascular AAA repair suggests that elevated plasma
MMP-9 may be a useful predictor of AAA expansion.20-22
These observations therefore have led to a growing appre-
ciation that MMP-9 might serve as a therapeutic target for
the pharmacologic management of patients with small
AAAs and a useful biomarker of aneurysm disease progres-
sion.
Accumulating evidence has shown that tetracycline an-
tibiotics effectively inhibit a broad spectrum of MMPs,
both in vitro and in animal models.23-26 These effects are
distinct from the antimicrobial activities of tetracyclines, as
shown with chemical modification of the tetracycline nu-
cleus to produce nonantibiotic chemically modified tetra-
cyclines (CMTs) as a novel class of MMP inhibitors.24 In
addition to their direct inhibition of MMP activities, tetra-
cyclines also may reduce cellular expression of some MMPs
(including MMP-9) and in certain circumstances, they can
accelerate the extracellular breakdown of proMMPs during
their activation.27 In several different animal models of
AAAs, treatment with either doxycycline or CMTs has
resulted in effective suppression of aneurysmal degenera-
tion associated with preservation of medial elastin and a
reduction in aortic wall production of MMP-9.15-18,28 In
an examination of the applicability of tetracycline deriva-
tives to the treatment of human AAAs, Franklin et al29
showed that exposure to tetracycline reduces the secretion
of MMP-9 by cultured explants of human AAA tissue and
that intraoperative administration of tetracycline leads to
rapid drug accumulation within aneurysm wall tissues. In a
study of patients who underwent open repair of AAAs,
Curci et al30 found that preoperative treatment with oral
doxycycline also results in a five-fold reduction in the
amount of MMP-9 expressed within aneurysm wall tissue.
These observations have led to considerable interest in
further evaluating MMP inhibition with doxycycline as a
potential therapeutic strategy in the management of pa-
tients with small asymptomatic AAAs.31,32
Because doxycycline has been successfully used in man-
agement of acne, periodontitis, and other chronic condi-
tions, it is generally expected to be safe and well tolerated
by patients with AAAs. Nonetheless, long-term treatment
with doxycycline has not been previously examined as a
specific form of drug therapy in elderly patients with aneu-
rysms or other forms of cardiovascular disease. To examine
the feasibility of this approach and to facilitate design of a
larger clinical trial, the primary purpose of this study was to
evaluate compliance, side effects, and safety of prolonged
treatment with doxycycline in patients with small asymp-
tomatic AAAs. A second goal of this study was to determine
how long-term administration of doxycycline affects circu-
lating plasma levels of MMP-9 in this patient population.
METHODS
Experimental design. Selection criteria for this study
included patients with asymptomatic infrarenal AAAs rang-
ing from 3.0 to 5.5 cm in maximal diameter, as measured
with either computed tomographic (CT) scan or abdomi-
nal ultrasound scan, for which no specific treatment was
otherwise planned. After review of the imaging studies to
verify initial aneurysm size, a focused medical history and
physical examination were performed by the participating
trial investigator. Peripheral venous blood was drawn for
measurement of serum creatinine and transaminase levels,
and a Euroqual health survey was completed. The compat-
ibility of doxycycline with the patient’s current medications
was analyzed with a computerized system (Drug-reax Mi-
cromedex Health Care Series, Englewood, Colo). Specific
exclusion criteria for the study were significant renal or
hepatic dysfunction (serum creatinine level, 2.0 mg/dL;
or transaminase levels greater than twice normal), a malig-
nant tumor, any known or suspected allergy to tetracycline
derivatives, or incompatibility of doxycycline with the pa-
tient’s concurrent medications. Written informed consent
was obtained from each patient in accordance with proto-
cols approved by the Institutional Review Board at each of
the participating institutions, and on entry into the study,
an additional sample of peripheral venous blood was ob-
tained for plasma analysis.
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Drug treatment and interval evaluation. All patients
underwent treatment with doxycycline (100 mg orally
twice per day). Each patient was initially provided with a
3-month supply of 100-mg doxycycline hyclate capsules
purchased from Danbury Pharmacal, Inc (Danbury, Conn)
and distributed from a centralized research pharmacy (Uni-
versity of Nebraska Medical Center, Omaha, Neb). Patients
were instructed to take one capsule with food twice each
day and to return any unused medications at the next
3-month follow-up visit. Patients were informed about side
effects anticipated during treatment with doxycycline, par-
ticularly photosensitivity, tooth discoloration, gastrointes-
tinal discomfort, and infections, and they were instructed to
promptly contact the participating investigator regarding
any problems that might potentially be related to their drug
treatment or aortic aneurysm disease.
Each patient underwent reexamination by the partici-
pating trial investigator at the end of the first 3 months and
was questioned about potential drug-related side effects,
development of new medical problems, or exacerbation of
an existing medical condition. Residual pill counts were
obtained, and any issues related to compliance with treat-
ment were thoroughly discussed with the patient. A follow-
up Euroqual health survey was completed, and peripheral
venipuncture was performed for plasma analysis. Each pa-
tient then was provided with a second 3-month supply of
doxycycline capsules. Similar procedures were followed at
the end of the 6-month study, at which time another
imaging study (CT or ultrasound) also was obtained to
reevaluate AAA size.
Management of side effects. During the course of
the study, the following guidelines were used in the man-
agement of side effects commonly associated with doxycy-
cline therapy. (1) Patients who reported gastrointestinal
symptoms during doxycycline treatment were advised to
take the medication with food. If this was unsuccessful in
prevention of gastrointestinal symptoms, it was recom-
mended that doxycycline be discontinued and that any
persistent symptoms be independently evaluated by the
patient’s personal physician. (2) For patients in whom a
significant episode of tetracycline-induced photosensitivity
developed, treatment with doxycycline was interrupted for
as long as 1 week to allow resolution of the skin reaction.
Methods to protect the skin from exposure to ultraviolet
light were discussed with the patient, and doxycycline
treatment then was resumed at the same dose if possible.
For any recurrent episode of photosensitivity, it was recom-
mended that doxycycline treatment be resumed at only half
the study dose (100 mg once per day); if this was unsuc-
cessful in prevention of further photosensitivity reactions,
withdrawal from the study was advised. (3) For patients in
whom tooth discoloration developed, vigorous oral hy-
giene was advised along with regular follow-up with a
dental technician for formal cleansing. If this was unsuc-
cessful in resolving tooth discoloration to the patient’s
satisfaction, withdrawal from the study was advised. (4) For
patients in whom any form of yeast infection developed
during the course of the study, it was recommended that
doxycycline treatment be interrupted for as long as 1 week
to permit resolution of the infection, along with vigorous
hygiene and antifungal treatment, followed by resumption
of the study medication. Significant adverse events were
defined as those prompting early withdrawal from the study
or necessitating interruption of treatment for 1 week or
more.
Plasma samples. Peripheral venous blood was drawn
into vacuum glass tubes containing ethylenediamine tet-
raacetate and centrifuged within 4 hours of procurement.
Plasma samples were aliquoted into 1-mL cryovials and
immediately stored at 70° C. Each sample was coded
with the specimen procurement date and patient identifi-
cation number assigned on entry into the trial, both to
maintain patient confidentiality and to blind samples dur-
ing biochemical analysis. Coded plasma samples were
shipped on dry ice to a centralized laboratory (Washington
University, St Louis, Mo) and stored as long as 3 months at
70° C before assay. One aliquot of each sample was
subsequently used for measurement of plasma doxycycline
concentration (3-month samples; n  23 suitable for anal-
ysis), and one for measurement of plasma MMP-9 levels
(baseline, 3-month, and 6-month samples; n 19 suitable
for analysis).
Measurement of plasma doxycycline levels. Plasma
doxycycline concentrations were measured with reverse-
phase high performance liquid chromatography with ultra-
violet detection, as previously described.33 This assay pro-
vides a lower limit of detection ranging from 0.025 to
0.125 ug/mL doxycycline in human plasma, with interas-
say and intraassay variability (relative standard deviations)
ranging from 3% to 7%.
Measurement of plasma matrix metalloproteinase-9
levels. Plasma MMP-9 concentrations were measured
with an enzyme-linked immunosorbent assay manufac-
tured by Amersham Life Science (Piscataway, NJ) and
distributed by Oncogene Research Products (Cambridge,
Mass), as previously described.20 This assay is based on a
two-site sandwich format with antibodies directed against
different epitopes of proMMP-9. It detects proMMP-9,
proMMP-9/tissue inhibitor of metalloproteinases
(TIMP)B1 complexes, and proMMP-9/TIMP-2 com-
plexes in human plasma over a range from 4 to 128 ng/mL;
in previous studies, negligible amounts of free, activated
MMP-9 have been shown to occur in the circulation.34
According to the manufacturer, this assay has a sensitivity of
0.6 ng/mL (two standard deviations above the zero dose
binding) and it exhibits less than 3% cross reactivity with
either active MMP-9 or active MMP-9/TIMP-1 com-
plexes, proMMP-1, proMMP-2, proMMP-3, TIMP-1, or
TIMP-2.
Each plasma sample was diluted 1:20 with buffer and
added to duplicate wells of a 96-well microplate containing
immobilized primary (anti-human MMP-9) antibody. Af-
ter washing and addition of the peroxidase-conjugated
antiBhuman MMP-9 secondary antibody, a chromogenic
substrate was added and the reaction products were quan-
tified with optical density at 450 nm with an automated
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microplate spectrophotometer (Bio-Tek Instruments, Inc,
Winooski, Vt). The average optical density for duplicate
wells was taken to determine the final concentration of
proMMP-9 in a given plasma sample, with taking into
account the dilution factor and interpolating from a stan-
dard curve that was simultaneously created with 4-ng/mL
to 128-ng/mL recombinant human proMMP-9 (provided
by the kit manufacturer). With the same assay system, we
have previously determined the upper limit of normal
plasma MMP-9 (mean plus 3 standard deviations) to be 85
ng/mL in a series of healthy volunteers.20 This level was
therefore chosen as a threshold to define the upper limit of
normal for plasma MMP-9 concentrations.
Data analysis and statistics. All group data are re-
ported as the mean the standard error of mean. Statistical
differences were analyzed with the Student t test for con-
tinuous variables or with the 2 test for categoric variables,
with P values less than .05 considered significant.
RESULTS
Baseline characteristics of the patient population.
Between February 1999 and January 2000, a total of 36
patients were enrolled in the study. As shown in Table I,
these patients included 30 men and six women, with a mean
age of 69  1 years (median, 69 years; range, 54 to 84
years). Twenty-seven patients (75%) underwent evaluation
with CT scan and nine (25%) with ultrasound scan, with
a mean AAA diameter at baseline of 41.0  1.0 mm
(median, 40.0 mm; range, 28 to 52 mm). With respect to
comorbidity and concomitant medical therapy, it is notable
that 25 of 36 patients (69%) were undergoing treatment
with an antihypertensive agent (13 with -blocker, six with
Table I. Individual patient characteristics, concurrent medications, and aneurysm size
Patient no. Age (y)/gender
Other medical treatment* AAA size (mm)†
AntiHTN Antilipid Anticoagulant Initial Final
1 70/M BB Yes ASA 37 US 35 US
2 74/M CCB – ASA, warf 47 US 48 US
3 62/M – – ASA 38 US 40 US
4 77/M – – ASA 28 US 27 US
5 77/M BB, CCB Yes ASA, warf 38 US 37 US
6 78/M CCB – – 42 US 49 US
7 68/M – – – 40 CT 42 CT
8 64/M BB – ASA 31 CT 30 CT
9 79/F – – – 47 CT 45 CT
10 71/F – Yes Plavix 33 US 33 US
11 57/M – – ASA 36 CT 36 CT
12 81/F ACEI Yes ASA 45 CT 45 CT
13 77/F ACEI – – 37 US W/drew
14 79/M ACEI Yes ASA 48 CT 49 CT
15 64/M ACEI – ASA 34 CT 35 CT
16 54/F BB – – 39 CT 39 CT
17 57/M – – ASA 35 CT 40 CT
18 67/M CCB Yes – 42 CT 40 CT
19 74/M BB Yes ASA 40 CT W/drew
20 65/M BB Yes ASA 35 CT 33 US
21 78/F – Yes ASA 43 CT W/drew
22 61/M BB Yes ASA 40 CT 55 CT
23 68/M ACEI, CCB Yes ASA 40 CT 40 CT
24 73/M – – – 45 CT 47 US
25 79/M – – – 45 CT 48 US
26 56/M BB – ASA 39 CT 40 CT
27 67/M CCB – – 45 CT 50 CT
28 49/M – Yes ASA 40 CT 44 CT
29 74/M – – ASA 45 US 49 CT
30 84/M – – ASA 45 CT 46 CT
31 73/M BB – – 50 CT 50 CT
32 61/M BB Yes – 52 CT 50 CT
33 79/M ACEI, BB Yes – 51 CT 59 CT
34 68/M – – ASA 35 CT 35 CT
35 81/M BB – ASA 48 CT 49 CT
36 64/M BB Yes – 41 CT 44 CT
*Other medical treatment (concurrent medications): AntiHTN, Medical treatment for hypertension; ACEI, angiotensin-converting enzyme inhibitor; BB,
-adrenergic receptor blocker; CCB, calcium channel blocker; antilipid, treatment with lipid-lowering agent (statin); ASA, acetylsalicylic acid; warf, warfarin;
Plavix, clopidogrel.
†AAA size was measured in mm diameter with either ultrasound (US) or computed tomographic scans; w/drew, patient withdrew from study.
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angiotensin-converting enzyme inhibitor, and six with cal-
cium channel blocker), 15 (42%) with a lipid-lowering
agent, and 23 (64%) with an anticoagulant or antithrom-
botic agent (22 with aspirin, two with warfarin, and one
with clopidogrel bisulfate). On the basis of clinical evalua-
tion and the Euroqual Health Survey, the study population
exhibited a relatively high degree of function before begin-
ning drug treatment (mean  standard error scores: mo-
bility, 1.25  0.07; self-care, 1.0  0.0; activity level,
1.17  0.06; pain, 1.5  0.1; and anxiety, 1.17  0.07).
Patient retention, side effects, and compliance with
study medication. Thirty-three of the 36 patients com-
pleted the entire course of doxycycline treatment, for an
overall retention rate of 92%. Patients who chose to with-
draw before the end of the 6-month period of study cited
refractory tetracycline-induced photosensitivity (n  1)
and persistent discoloration of the teeth (n  1) as the
principal reasons for withdrawing from the study, and the
third patient cited anxiety raised by an article in a weekly
newsmagazine. These issues arose between the second and
third months in the first two patients and between the third
and fourth months in the third.
One or more treatment-related side effects occurred in
22 of the 36 patients initially enrolled, but most of these
events were mild and self limited (Table II). Although 11
patients reported at least one episode of tetracycline-
induced photosensitivity for an overall incidence rate of
30.5%, these episodes were generally controlled with limit-
ing sun exposure and with a temporary reduction in drug
administration. Two patients had to interrupt therapy for at
least 1 week because of a pronounced photosensitivity
reaction (but then resumed treatment after its resolution),
Table II. Incidence and nature of side effects in individual patients
Patient no.
First 3-month period Second 3-month period
CommentsGI PS DD Other GI PS DD Other
1 – – – – – – – –
2 – PS – – – – – –
3 – – – – – – – –
4 – – – – – – – –
5 – – – – – PS – –
6 – – – – – – – –
7 – – – – – – – –
8 – – – – – – – –
9 – – – – – – – –
10 – – DD – – PS* DD –
11 – PS – – – – – R
12 – – – – – – – –
13 – – DD* – W/drew DD
14 – – – – GI – – R
15 – – – – – – – –
16 GI – – I* – – – – Yeast infection
17 – – – – – – – –
18 – – DD – – – – –
19 – PS – – – PS – R* W/drew, PS
20 (GI) – – – – – – –
21 (GI) – – A W/drew Magazine article
22 (GI) – – – – PS – –
23 – PS – – – PS – –
24 – PS – I – PS – R
25 – – – – – – – –
26 – PS* – – GI – – –
27 – – – MI – – – –
28 – – – – – – – –
29 – PS – – – – – –
30 – – – – – PS – –
31 GI – – – – – – –
32 – – – – GI – – –
33 (GI) – – – GI – – –
34 – – – – – – – –
35 – – – – – – – –
36 – PS – – – PS – –
*Designates that temporary interruption in treatment greater than 1 week or dose adjustment was made to alleviate side effect indicated.
Parentheses indicate mild side effect for which no significant treatment measures were necessary. W/drew, Patient withdrew from study.
Primary treatment-related side effects: GI, Gastrointestinal symptoms; PS, photosensitivity; DD, dental discoloration.
Other side effects: R, Rash unrelated to photosensitivity; I, infection; A, anxiety; MI, myocardial infarction.
Absence of particular side effect is indicated with (–).
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and one patient eventually withdrew from the study be-
cause of refractory photosensitivity. Gastrointestinal symp-
toms also occurred at some point during the study in nine
patients, for an overall incidence rate of 25%. These symp-
toms consisted primarily of nonspecific symptoms, such as
nausea, bloating, mild cramping, or gastroesophageal re-
flux, and no patient reported gastrointestinal side effects
that could not be alleviated or improved by taking the
medication with meals. Three patients had slight discolor-
ation of the teeth develop during doxycycline treatment,
for an overall incidence rate of 8.3%. Two of these patients
were not substantially bothered by the appearance and
chose to continue in the trial with more vigorous dental
hygiene and periodic dental cleaning, but one patient with-
drew from the study for this reason. Although no patient
had a bacterial infection develop during the period of drug
treatment, one (2.8%) had a yeast infection in the groin
develop that necessitated temporary interruption of treat-
ment. Finally, one patient had idiopathic plantar fasciitis
develop and one had an acute myocardial infarction 2
months after enrollment. The latter patient chose to con-
tinue on doxycycline during cardiac recovery and main-
tained treatment through the duration of the trial. Thus,
significant adverse side effects attributable to doxycycline
occurred in only five of the 36 patients initially enrolled
(13.9%), with photosensitivity in three (8.3%), discolora-
tion of the teeth in one (2.8%), and candidiasis in one
(2.8%).
With patient self-report and assessment of pill counts at
each follow-up visit, a high rate of compliance with doxy-
cycline treatment was seen throughout the period of study.
And the results of the Euroqual Health Survey indicated no
significant changes over the course of the 6-month investi-
gation (mean  standard error scores at 6 months: mobil-
ity, 1.22 0.07; self-care, 1.0 0.0; activity level, 1.13
0.06; pain, 1.5  0.1; and anxiety, 1.19  0.08).
Plasma doxycycline levels. Measurements of plasma
doxycycline concentration were obtained midway through
the study in 23 of the 36 patients, both to assess the range
of plasma levels that can be expected during long-term
drug administration and to confirm compliance with treat-
ment. The mean plasma doxycycline level at 3 months was
4.62 0.68 g/mL, with a median of 3.64 g/mL and a
range of 1.31 to 14.39 g/mL. On the basis of previous
studies, these circulating levels of doxycycline were well
within the range necessary to achieve effective MMP inhi-
bition.29,30,33
Aneurysm expansion. For the group of 33 patients
that completed 6 months of doxycycline treatment, the
mean aneurysm size at the beginning of the study was
41.4  1.0 mm (median, 40.0 mm; range, 28 to 52 mm).
Repeat measurements of aneurysm size at the end of 6
months revealed a mean diameter of 42.7  1.3 mm
(median, 44.0; range, 27 to 59 mm), showing no signifi-
cant difference over the interval of the trial (Fig 1, A).
Notable is that only five of 33 patients (15%) had significant
aneurysm growth (	5 mm) and that the overall rate of
expansion was only 0.63%  0.25% per month of follow-
up. Although this observed rate of aneurysm growth com-
pares favorably with that described in previous studies (in
which small AAAs have been found to enlarge at an average
rate of 4 to 5 mm per year, or approximately 0.8% per
month of follow-up),5 these findings must be considered
with caution given the preliminary nature of this study.
Nonetheless, treatment with doxycycline can be considered
safe in patients with AAAs because the mean extent of
growth observed (1.7 mm) was no greater than that antic-
ipated for aneurysms of this size (2.7 mm). As illustrated
with Fig 1 , B, no correlation was seen between changes in
aneurysm size and individual plasma doxycycline levels.
Plasma matrix metalloproteinase-9 levels. Evalu-
able plasma MMP-9 levels were obtained for 19 of the 36
patients participating in the study, including 15 men and
four women, with a mean age of 68.9  1.9 years (Table
III). At the start of the study, nine of these patients (47%)
had a plasma MMP-9 level above the upper limit of normal
for our laboratory (	85 ng/mL) and the mean baseline
plasma MMP-9 level for the entire group was 118.9 37.9
Fig 1. Aneurysm size before and after treatment with doxycycline. A, Aneurysm diameter was measured with
abdominal ultrasound or CT scans. No significant difference was seen between measurements obtained at baseline and
after 6 months of treatment with doxycycline (data shown represent mean  standard error of mean). B, Scatter plot
compares plasma doxycycline concentration with proportional changes in aneurysm size for individual patients.
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ng/mL (median, 75.2 ng/mL; range, 0.0 to 727 ng/mL).
This is consistent with our previous observations on plasma
MMP-9 levels in patients undergoing elective repair of
large AAAs, where elevated plasma MMP-9 levels were
present in about 50% of the patients and the mean level
before surgical treatment was 99.4  17.4 ng/mL.20
As illustrated in Fig 2, A, a progressive decline was seen
in the mean plasma MMP-9 level after beginning treatment
with doxycycline, even during the relatively short period of
this study. The mean plasma MMP-9 level after 3 months
of treatment was 83.8  32.9 ng/mL (median, 32.9 ng/
mL; range, 0 to 528 ng/mL), and it decreased further after
6 months to 66.4  24.2 ng/mL (median, 24.2 ng/mL;
range, 0 to 417 ng/mL). The difference between baseline
MMP-9 levels and those obtained after 6 months of treat-
ment was highly significant (P  .022). Thus, the overall
net change in plasma MMP-9 was52.5 21.0 ng/mL at
6 months, and the mean percentage change from baseline
levels was 29.2%  16.9%.
With respect to individual patients, 14 of 19 (74%) had
a decrease in plasma MMP-9 at 6 months compared with
the pretreatment baseline level, and 10 of these had a
Fig 2. Plasma MMP-9 levels before and after treatment with doxycycline. Plasma concentrations of MMP-9 were
measured with enzyme-linked immunosorbent assay, as described in Methods. A, Group data represent mean 
standard error of mean of values obtained at baseline, 3 months, and 6 months. B, Changes in plasma MMP-9 levels for
patients with either elevated or normal levels at baseline. C, Plot of individual plasma MMP-9 levels at baseline and after
6 months of treatment with doxycycline. ULN, Upper limit of normal.
Table III. Plasma MMP-9 levels in individual patients
Patient no.
Plasma MMP-9* AAA size†
Baseline
(ng/mL)
3 Months
(ng/mL)
6 Months
(ng/mL)
Overall
change
Initial
(mm)
Final
(mm)
Overall
(mm) Change
1 66.5 38.5 0 –100% 37 US 35 US –2 5.4%
2 37.5 0.0 17.3 –54% 47 US 48 US 1 2.1%
6 0.0 0.0 20.8 21% 42 US 49 US 7 16.7%
7 21.1 14.9 44.6 111% 40 CT 42 CT 2 5.0%
8 0.0 40.5 0 0% 31 CT 30 CT –1 3.2%
9 51.4 42.7 121.7 137% 47 CT 45 CT –2 4.3%
10 125.9 177.8 3 –98% 33 US 33 US 0 0.0%
11 41.0 63.0 31.8 –22% 36 CT 36 CT 0 0.0%
12 726.8 528.1 417.2 –43% 45 CT 45 CT 0 0.0%
14 75.2 103.6 24 –68% 48 CT 49 CT 1 2.1%
15 323.6 – 211.9 –34% 34 CT 35 CT 1 2.9%
16 86.5 61 7.8 –91% 39 CT 39 CT 0 0.0%
17 136.2 38.1 28.2 –79% 35 CT 40 CT 5 14.3%
18 46.8 27.5 13 –72% 42 CT 40 CT –2 4.8%
20 104.3 2.5 41.3 –61% 35 CT 33 US –2 5.7%
22 95.6 11.4 200.5 108% 40 CT 55 CT 15 37.5%
23 96.2 10.3 53 –45% 40 CT 40 CT 0 0.0%
24 38.5 0 9.8 –75% 45 CT 47 US 2 4.4%
25 185.9 347.7 15.6 –92% 45 CT 48 US 3 6.6%
*Plasma MMP-9 concentrations were measured with enzyme-linked immunosorbent assay as described in Methods. Overall change was determined as percent
difference between baseline and 6-month samples.
†AAA size was measured in mm diameter with either ultrasound (US) or computed tomographic scans.
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decrease greater than 50%. One of the 19 patients had no
change in plasma MMP-9 level, and four (21%) actually had
an increase. After 6 months of treatment with doxycycline,
only four patients (21%) had elevated plasma MMP-9 levels
compared with 47% at baseline (P  .05, with 2 analysis).
No detectable correlation was found between changes in
plasma MMP-9 levels and plasma levels of doxycycline
(data not shown).
With evaluation as a potential biomarker of aneurysm
disease, it is notable that the greatest decreases in plasma
MMP-9 concentration were observed in patients who had
elevated levels at the start of the study. For this subgroup of
patients (n 9), the mean plasma MMP-9 levels before and
after 6 months of treatment were 209.0 69.3 ng/mL and
108.7  46.9 ng/mL, respectively, with a net change of
100.3  36.6 ng/mL (Fig 2 , B). The mean percentage
change in plasma MMP-9 for this group was 48.0% 
21.2% (Fig 3, A). Eight of the nine individual patients
(89%) had a decrease in plasma MMP-9 after 6 months of
treatment, and five of these had a decrease greater than 50%
of their baseline levels, whereas only one of the nine pa-
tients (11%) had an increase in plasma MMP-9.
For the subgroup of patients who had normal plasma
MMP-9 levels at the start of the study (n  10), the mean
plasma MMP-9 levels before and after treatment were
37.8  7.9 ng/mL and 28.3  11.2 ng/mL, respectively,
with a net change of only9.5 12.7 ng/mL (Fig 2 , B).
The mean percentage change in plasma MMP-9 for this
group was also negligible (12.2% 25.6%; Fig 3 , A). Six
of the 10 individual patients (60%) had a decrease in plasma
MMP-9 after 6 months, and all of these had a decrease
greater than 50% of their baseline levels; however, three of
the 10 patients (30%) had an increase in plasma MMP-9
(two more than 100% of their baseline levels), and one
patient had no change.
No demonstrable correlation was found between
changes in plasma MMP-9 concentration and changes in
aneurysm size for the 19 patients in whom both endpoint
measures were obtained (Fig 3 , B). The mean aneurysm
diameter in this group was 40  1 mm at the start of the
study and 42  2 mm after 6 months, a difference consid-
ered insignificant but consistent with the average rate of
aneurysm growth (approximately 5 mm per year). None-
theless, important trends were identified when the decrease
in plasma MMP-9 was evaluated as a potential predictor of
successful treatment in individual patients. Thus, of the 14
patients who had a decrease in plasma MMP-9, the mean
change in aneurysm size was only 1  1 mm diameter,
and just two of these patients had an increase in aneurysm
diameter greater than 2 mm (3 mm and 5 mm, respec-
tively). In contrast, two of the four patients who had an
increase in plasma MMP-9 also had an unusually rapid
increase in aneurysm diameter (7 mm and 15 mm,
respectively), and the remaining two patients had no signif-
icant change in aneurysm size (2 mm and 2 mm,
respectively). Indeed, the single patient with the greatest
increase in aneurysm size (patient 22: 37.5% increase, from
40 mm to 55 mm) also had one of the greatest observed
increases in plasma MMP-9 concentration (108% in-
crease, from 95.6 ng/mL to 200.5 ng/mL). Finally, the
mean change in aneurysm size was 4  3 mm diameter
for the five patients who did not have a decrease in plasma
MMP-9. Although this appears to be greater than the
change in aneurysm size for patients who did have a de-
crease in plasma MMP-9, this difference did not reach a
statistically significant level.
DISCUSSION
The results of this study show for the first time that
patients with small asymptomatic AAAs can be safely
treated with doxycycline over a sustained period of time,
with a high degree of compliance and no apparent adverse
effects on aneurysm expansion. Secondly, our results indi-
cate that serial measures of plasma MMP-9 concentration
Fig 3. Changes in plasma MMP-9 levels. A, Scatter plot shows proportional changes in plasma MMP-9 concentration
after 6 months of treatment with doxycycline, for all patients and those with either elevated or normal levels at baseline.
Open bars indicate mean  standard error of mean for each group. B, Scatter plot compares proportional changes in
plasma MMP-9 level with proportional changes in aneurysm size for individual patients.
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may have biologic and clinical significance, both in the
follow-up of patients with small asymptomatic AAAs and in
the evaluation of the effects of doxycycline treatment in this
patient population.
Despite abundant evidence that treatment with doxy-
cycline can inhibit the development and growth of experi-
mental aortic aneurysms and the long-established clinical
safety of doxycycline for use in other conditions, it has
become apparent that several critical questions need to be
addressed before undertaking more definitive clinical trials
to evaluate this potential therapeutic strategy. The first of
these questions is related to the prolonged use of doxycy-
cline in the elderly patient population affected with AAAs.
Although chronic doxycycline treatment has been used
extensively in younger patients with severe acne and in
small cohorts of elderly patients with recurrent bacterial
infections, these studies did not provide sufficient informa-
tion on how chronic administration of the drug would be
tolerated in a representative population of patients with
small AAAs. Accurate estimates of the attrition rate that can
be expected as the result of drug intolerance and the
incidence rate of adverse side effects were therefore consid-
ered essential for the design of a sufficiently powered pro-
spective clinical trial. Secondly, evaluation of whether treat-
ment with doxycycline might have any unanticipated
adverse effects on the growth rate of small AAAs was
deemed necessary. Thus, the primary purpose of this study
was to assess patient compliance, side effects, and clinical
safety during prolonged treatment with doxycycline in a
population of patients with small asymptomatic AAAs.
Compliance and treatment-related side effects. Al-
though this study was successful as a phase II clinical trial,
several intrinsic limitations preclude generalizations about
the potential clinical use of doxycycline for patients with
small asymptomatic AAAs. First, the dose selected here
(100 mg orally twice per day) was considered the upper
limit achievable for prolonged clinical use. This dose was
selected as a commonly used regimen for antimicrobial
therapy and is supported by treatment schedules used in
animal models of AAAs and preliminary clinical experi-
ments that show sufficient plasma levels of doxycycline to
inhibit MMPs in vitro. However, this dose may still not be
sufficient or optimal for achieving aneurysm-suppressing
activity in humans. Second, the incidence of side effects
attributable to doxycycline is dose related. Although few
patients in this study had significant side effects and the
overall rate of compliance with medication was remarkably
high, this may not persist in a larger population of patients
or over longer periods of drug administration. Nonethe-
less, in an ongoing study of elderly women receiving the
same dose of doxycycline (100 mg twice per day) to sup-
press the progression of knee joint destruction caused by
osteoarthritis, Brandt and colleagues have found a similarly
high rate of compliance and low incidence rate of adverse
effects as observed here (Kenneth D. Brandt, personal
communication, December 2001).
The most frequent side effects observed in this study
were nonspecific gastrointestinal symptoms and tetracycline-
associated photosensitivity. Gastrointestinal symptoms are
not uncommon during tetracycline administration, partic-
ularly with the first few doses, and can usually be alleviated
by taking the medication with meals. This was observed
throughout our study, and with proper instruction, no
patients had to interrupt or discontinue treatment for this
reason. Photosensitivity is an idiosyncratic (ie, nonallergic)
reaction related to photoactivation of tetracycline com-
pounds that have accumulated within the epidermis and
superficial dermis during systemic treatment, in which ul-
traviolet light absorbed by the tetracycline ring leads to the
local generation of free radicals and epidermal necrosis.35
The incidence of tetracycline-induced photosensitivity is
dose related, the clinical manifestations are similar to a
severe sunburn, and the course of these reactions is self
limited. Several of the patients in this study had mild
photosensitivity reactions develop that were subsequently
prevented by limiting exposure to ultraviolet light; their
willingness to follow such precautions attests to the high
level of motivation patients might have for a potential
pharmacologic therapy to suppress AAA growth.
A second adverse effect observed in this study was
reversible tooth discoloration. Unlike the tooth discolora-
tion associated with use of tetracyclines in infancy and
childhood, in which the incorporation of tetracyclines into
the developing enamel leads to permanent yellowing, the
tooth discoloration seen in adults is related to the binding
of tetracyclines to secreted oral proteins and the adsorption
of these complexes on the tooth surface.36 This effect is
thereby usually reversible with vigorous dental hygiene and
was easily managed by several of the patients in this study.
Additional limitations of prolonged treatment with
doxycycline are related to its antimicrobial effects. For exam-
ple, potential development of bacterial resistance or secondary
infection with other organisms (ie, Candida spp) both
remain of concern during prolonged treatment with doxy-
cycline. Bacterial resistance to tetracyclines is probably not
as clinically important as it is with other antibiotics because
exposure to tetracyclines is already widespread in the envi-
ronment (indeed, tetracyclines are used in substantially
greater quantities in the agriculture and livestock industries
than in human medicine)37 and because few clinical infec-
tions exist for which tetracyclines are the most preferred or
specifically required treatment.38 Because the molecular
mechanisms of bacterial resistance to tetracyclines are quite
distinct from those for other families of antimicrobial
agents, there is also a low incidence rate of cross resistance
between tetracyclines and other antibiotics.39 Nonetheless,
tetracycline-induced alterations in bacterial flora may lead
to oral candidiasis, vulvovaginitis, and pruritis ani because
of overgrowth of Candida albicans, and superimposed
yeast infections would remain of particular concern in
women and immunocompromised patients. Although we
observed only one patient with a yeast infection in this
study, this complication will clearly need to be monitored
carefully in future investigations with long-term adminis-
tration of doxcycline. It is also possible that the risk of yeast
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infections can be substantially reduced with use of lower
doses of doxycycline or alternative treatment schedules.
Safety of doxycycline with respect to abdominal
aortic aneurysm expansion. Another aspect of this study
was to evaluate whether doxycycline had any potential
adverse influence on aneurysm growth rate as a means to
assess whether treatment with doxycycline is a clinically safe
therapeutic strategy for further investigation. This was con-
sidered important because experimental animal models do
not recapitulate all of the features of AAAs as they occur in
humans and because doxycycline has additional properties
that may have had an adverse influence on aneurysmal
lesions (such as its ability to inhibit cellular migration and to
induce apoptosis in some cell types).40,41 Nonetheless, we
observed no significant difference in mean AAA size be-
tween baseline measurements and those obtained after 6
months of treatment, and the overall rate of aneurysm
growth was similar to that reported in previous studies of
untreated patients.5 Therefore, conclusion that sustained
treatment with doxycycline does not appear to have any
adverse effects on aneurysm growth or susceptibility to
rupture over a 6-month period is possible. This information
will allow investigators to proceed with greater confidence
toward further studies intended to examine the therapeutic
efficacy of doxycycline in this patient population. It is
important to reiterate that the design of this study purpose-
fully precluded any conclusions regarding the actual thera-
peutic efficacy of doxycycline on the growth of small AAAs
because of the relatively limited number of patients and the
short duration of treatment. Because aneurysm expansion is
generally measured over several years and does not occur in
a predictable manner in any individual patient, a larger
clinical study with much longer follow-up will be needed to
address this question.
Plasma matrix metalloproteinase-9. The secondary
goal of this study was to investigate the use of serial mea-
sures of plasma MMP-9 concentration as a potential marker
of aneurysm disease activity in patients undergoing doxy-
cycline treatment. This was based on previous studies that
showed that plasma MMP-9 levels are increased in many
patients with AAAs and that elevated plasma MMP-9 levels
subsequently decrease in patients undergoing aneurysm
repair19,20,22 and on preliminary evidence that elevated
plasma MMP-9 levels may be associated with an increased
rate of aneurysm expansion.21 Consistent with earlier find-
ings that short-term treatment with doxycycline is associ-
ated with a reduction in aortic wall MMP-9 expression,30
we also found that mean plasma MMP-9 levels were signif-
icantly reduced after prolonged treatment with doxycy-
cline. This observation thereby lends support to the notion
that plasma MMP-9 levels might accurately reflect biologic
events occurring with aneurysm wall tissue and that doxy-
cycline is capable of effectively suppressing MMP-9 expres-
sion in many patients with AAAs. Because patients with
elevated plasma MMP-9 levels may represent those at
greatest risk of aneurysm expansion, particularly interesting
is that the greatest decreases in plasma MMP-9 concentra-
tion were observed in this group. Also worth noting is that
patients with persistently elevated plasma levels of MMP-9
appeared to show a trend toward more rapid aneurysm
expansion than those in whom plasma MMP-9 levels de-
creased after doxycycline treatment. These findings are
obviously quite valuable given the potential to measure
plasma MMP-9 levels as a surrogate marker of pathologic
events within the aneurysm wall during the follow-up of
patients with AAAs and during doxycycline treatment. De-
spite these encouraging findings, further studies are needed
before the predictive value of plasma MMP-9 levels can be
convincingly shown.
Like other tetracyclines, doxycycline exhibits inhibitory
activity for a broad spectrum of MMPs and is therefore
classified as a nonselective MMP antagonist. Thus, any
beneficial effect that doxycycline might have on aneurysm
expansion cannot be attributed solely to inhibition of
MMP-9; rather, suppression of MMP-9 may simply serve as
an easily measured index of the biologic changes induced
by doxycycline treatment. Because metalloproteinase-
mediated connective tissue destruction is often the result
of many different enzymes acting in concert (including
serine and cysteine proteases), broad-spectrum MMP inhi-
bition may actually be a preferred therapeutic strategy for
complex degenerative disorders and the pleiotropic effects
of tetracyclines might thereby offer an ideal approach.24
Studies with tetracyclines as MMP inhibitors are nonethe-
less difficult to interpret with respect to the mechanistic role
that individual enzymes might play in connective tissue
destruction and disease progression. Another difficulty re-
garding mechanistic interpretation relates to the antibiotic
activity of doxycycline with respect to any beneficial effects
that the drug might have on human AAAs, especially given
evidence that chronic infection with Chlamydia pneu-
moniae might participate in the pathophysiology of athero-
sclerotic vascular disease.42,43 Although C pneumoniae is
usually sensitive to treatment with tetracyclines, prolonged
therapy with doxycycline may not diminish serologic mark-
ers of chlamydial infection, making it difficult to ascertain
whether any beneficial effects of doxycycline on the pro-
gression of aneurysm disease can be attributed solely to its
metalloproteinase-inhibiting activity and not to concomi-
tant eradication of C pneumoniae within aneurysm tissue.44
This issue will need be addressed in future studies with the
use of either subantimicrobial formulations of doxycycline
(ie, Periostat), nonantimicrobial CMTs, or other nonantibi-
otic MMP inhibitors (eg, hydroxamic acid derivatives).45,46
Finally, it is necessary to insert a note of caution regard-
ing the premature use of doxycycline in patients with AAAs.
Although MMP inhibition remains a promising treatment
strategy for future development, it is not yet known
whether doxycycline (or any other pharmaceutic agent) can
actually influence the growth rate of small aortic aneurysms.
This concern thereby reinforces the need for prospective,
randomized, placebo-controlled clinical trials to determine
whether pharmacologic strategies will have clinical benefits
for patients with AAAs.
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